This prospective and retrospective study was performed in multiple local centers. The local ethics committee approved the study, and the patients signed informed consent.
In the last five years, one hundred twenty patients with left main disease > 50% were subjected to stenting with drug-eluted stents.
All patients were subjected to detailed history taking with particular emphasis on acute coronary syndrome, angina duration, class, previous coronary interventions, and medications. In addition, 12 lead ECGs were revised with an evaluation of ST/T changes and any old infarction. An echocardiographic examination was done on all patients following the recommendations of the American Society of Cardiology [23]. Ejection fraction, LV diameters, and wall motion were recorded. Laboratory testing included kidney function, lipid profile, and blood sugar.
Risk assessment was calculated for every patient, including Euro SCORE and Syntax score.
Medications: All patients received clopidogrel and aspirin before the planned procedure. Anticoagulation with unfractionated heparin in a dose of 10000 IU was given at the beginning of the PCI. Post PCI, all patients received B blockers, ACE inhibitors, statins, and dual antiplatelets in the guidelines recommended doses.
PCI technique: A steerable guidewire was advanced in LAD, followed by PCI with pre-dilatation or direct stenting according to the operator's discretion. One or two stent strategy was utilized according to the situation of the lesions.
Study outcomes
1. Procedural outcomes:
a. Thrombolysis in Myocardial Infarction (TIMI) flow grade was graded Grade 0, absence of antegrade flow beyond the point of occlusion; Grade1, partial penetration of contrast agent beyond the obstruction but incomplete distal filling; Grade 2, patency with opacification of the entire distal vessel but with delayed filling or washout of contrast agent; and Grade 3, normal flow.
b. We defined the procedural success rate as residual stenosis of less than 20% and establishment of Thrombolysis in Myocardial Infarction (TIMI)-3 flow. Without major periprocedural adverse events (Death, myocardial infarction, emergency revascularization).
2. In-hospital outcomes
A. Death. B. Myocardial infarction. C. Cerebrovascular stroke. D. Re-intervention: Target Vessel Revascularization (TVR), Target Lesion Revascularization (TLR), and Non-Target Vessel Revascularization (Non- TVR). E. Heart Failure.
3. Thirty days outcomes
a. Death. B. New angina or myocardial infarction. C. Cerebrovascular stroke.
d. Re-intervention: (TVR), (TLR), and (Non- TVR). E. Heart Failure.
a. We recorded six-month outcomes as death, cerebrovascular stroke, re-intervention (TVR), (TLR), and (Non- TVR), New angina, and Heart Failure.
Study endpoints: Primary endpoints are major cardiovascular events at 30 days and six months, defined as death, myocardial infarction, cerebrovascular stroke, and re-intervention: TVR, TLR, and Non-TVR.
All methods were performed following the relevant guidelines and regulations
Statistical analysis of the data
Data were fed to the computer and analyzed using IBM SPSS version 20.0. (Armonk, NY: IBM Corp) Qualitative data were described using numbers and percentages. The Kolmogorov-Smirnov test was used to verify the normality of distribution. Quantitative data were described using range (minimum and maximum), mean, standard deviation, and median. The significance of the obtained results was judged at the 5% level. The used tests were: Chi-square test: For categorical variables, to compare different groups. Fisher's Exact or Monte Carlo correction: Correction for chi-square when more than 20% of the cells have an expected count of less than 5. Student t-test: For normally distributed quantitative variables, to compare two studied groups.